Volume 75, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Some have claimed that triclabendazole, a safe and efficacious drug for the treatment of fascioliasis, also exhibits antischistosomal properties, but results are conflicting. We assessed the effect of triclabendazole and its two main metabolites against two different strains of harbored in mice. Low worm burden reductions (18.6–35.9%) were observed in mice infected with an Egyptian strain of and treated with a single dose of 120 mg/kg 3 days before infection or single/double doses of 120–200 mg/kg 7 weeks after infection. Triclabendazole failed to significantly reduce hepatic and intestinal tissue egg loads, and eggs of all developmental stages were observed. Administration of 400 mg/kg of either triclabendazole, triclabendazole sulphone, or triclabendazole sulfphoxide to mice infected with a Liberian strain of resulted in worm burden reductions < 10%. In comparison, high worm burden reductions (82–100%) were observed in –infected mice treated with single oral doses of 400, 500, or 500 mg/kg twice a day praziquantel, regardless of the strain. We conclude that triclabendazole and its main metabolites display weak and inconsistent schistosomicidal activities.


Article metrics loading...

Loading full text...

Full text loading...



  1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, 2006. Schistosomiasis and water resources development: systematic review, meta-analysis and estimates of people at risk. Lancet Infect Dis 6 : 411–425.
  2. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D, 2003. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86 : 125–139.
  3. Utzinger J, Keiser J, 2004. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5 : 263–285.
  4. King CH, Dickman K, Tisch DJ, 2005. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365 : 1561–1569.
  5. Engels D, Chitsulo L, Montresor A, Savioli L, 2002. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 82 : 139–146.
  6. WHO, 2002. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis: Report of a WHO Expert Committee. Geneva: World Health Organization.
  7. Seubert J, Pohlke R, Loebich F, 1977. Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experientia 33 : 1036–1037.
  8. Chen MG, 2005. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years’ experience. Acta Trop 96 : 168–176.
  9. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH, 2003. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19 : 509–515.
  10. Cioli D, 2000. Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 13 : 659–663.
  11. Danso-Appiah A, de Vlas SJ, 2002. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 18 : 125–129.
  12. Cioli D, Pica-Mattoccia L, 2003. Praziquantel. Parasitol Res 90 (suppl 1): S3–S9.
  13. Keiser J, Engels D, Büscher G, Utzinger J, 2005. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Invest Drugs 14 : 1513–1526.
  14. El Sayed MH, Allam AF, 1997. Effect of triclabendazole on the tegument of Schistosoma mansoni: a scanning electron microscopic study. J Egypt Soc Parasitol 27 : 143–152.
  15. Khalil SS, 2000. On the schistosomicidal effect of triclabendazole: an experimental study. J Egypt Soc Parasitol 30 : 799–808.
  16. Coles GC, 1986. Anthelmintic activity of triclabendazole. J Helminthol 60 : 210–212.
  17. TDR, 2005. Seventeenth Programme Report (Progress 2003–2004): Making Health Research Work for Poor People. Geneva: Tropical Disease Research.
  18. Duvall RH, DeWitt WB, 1967. An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 16 : 483–486.
  19. Pellegrino J, Oliveira CA, Faria J, Cunha AS, 1962. New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am J Trop Med Hyg 11 : 201–215.
  20. Kloetzel K, 1967. A suggestion for the prevention of severe clinical forms of schistosomiasis mansoni. Bull World Health Organ 37 : 686–687.
  21. Soliman GN, el Assal FM, Mansour NS, Garo K, 1986. Comparison of two Egyptian strains of Schistosoma mansoni in hamsters. Z Parasitenkd 72 : 353–363.
  22. el Mansoury ST, Bayoumi DM, 1995. Pathologic and ultrastructure characterization of two different strains of Schistosoma mansoni. J Egypt Soc Parasitol 25 : 1–10.
  23. World Health Organization, 1993. Evaluation of Certain Veterinary Drug Residues in Food. Geneva: World Health Organization.
  24. Manhaes-Rocha DA, Conte FP, Fidalgo-Neto AA, De-Oliveira AC, Ribeiro-Pinto LF, Paumgartten FJ, 2005. Alterations of hepatic microsomal enzymes in the early phase of murine schistosomiasis. Acta Trop 95 : 58–66.
  25. Maffei Facino R, Carini M, 1982. Loss of substrate binding capacity of the hepatic microsomal cytochrome P-450 in Fasciola hepatica infected rats: toxicological implications. Farmaco [Sci] 37 : 184–191.
  26. Sheir Z, Nasr AA, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad SM, 2001. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 65 : 700–704.
  27. Abo-Madyan AA, Morsy TA, Motawea SM, 2004. Efficacy of myrrh in the treatment of schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate, Egypt. J Egypt Soc Parasitol 34 : 423–446.
  28. Botros S, William S, Ebeid F, Cioli D, Katz N, Day TA, Bennett JL, 2004. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 71 : 206–210.
  29. Barakat R, Elmorshedy H, Fenwick A, 2005. Efficacy of myrrh in the treatment of human schistosomiasis mansoni. Am J Trop Med Hyg 73 : 365–367.

Data & Media loading...

  • Received : 23 Jan 2006
  • Accepted : 01 Apr 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error